

1 **Genetically proxied inhibition of L-2-hydroxyglutarate**
2 **dehydrogenase and the risk of coronary artery disease: A**
3 **Mendelian randomization study**

4

5 Euijun Song, M.D.

6 *Yonsei University College of Medicine, Seoul, Republic of Korea*

7

8

9 Correspondence: drjunsong@gmail.com (Euijun Song)

10

11 **Conflicts of interest:** All authors have no financial conflicts of interest to declare.

12

13 **Abstract**

14 **Background:** L-2-hydroxyglutarate dehydrogenase (L2HGDH) deletion-induced L-2-
15 hydroxyglutarate accumulation plays a cardioprotective role in hypoxic conditions.

16 However, there has been no causal evidence in real-world clinical data. We aimed to
17 examine the causal effects of *L2HGDH* inhibition on coronary artery disease (CAD) and
18 myocardial infarction (MI) using Mendelian randomization (MR) analysis.

19 **Methods:** We used nine *L2HGDH*-proxied genetic variants associated with blood 2-
20 hydroxyglutarate levels as genetic instruments, and performed two-sample MR analysis
21 using the CARDIoGRAMplusC4D meta-analysis datasets of CAD (60,801 CAD cases
22 and 123,504 controls) and MI (34,541 MI cases and 261,984 controls).

23 **Results:** Genetically proxied inhibition of *L2HGDH* associated with 2-hydroxyglutarate
24 levels potentially decreased the risk of CAD (odds ratio [OR] 0.486, 95% confidence
25 interval [CI] 0.242–0.977, $P=0.043$) but was not associated with the risk of MI (OR
26 0.676, 95% CI 0.312–1.463, $P=0.320$). This potentially causal association between
27 *L2HGDH* inhibition and CAD was unlikely to be biased by horizontal pleiotropy, whereas
28 there might be a weak instrument bias.

29 **Conclusion:** Our MR analysis suggests the potential association between genetically
30 proxied inhibition of *L2HGDH* and CAD. Our findings may have therapeutic implications
31 for L2HGDH inhibitors in CAD, and further large-scale clinical studies are needed.

32

33 **Keywords:** L-2-hydroxyglutarate dehydrogenase; coronary artery disease;
34 therapeutics; Mendelian randomization; metabolism

35

36 **1. Introduction**

37 L-2-hydroxyglutarate plays a pivotal role in cytoplasmic and mitochondrial energy
38 metabolism to maintain redox regulation [1]. Hypoxia increases cellular L-2-
39 hydroxyglutarate, which is produced from α -ketoglutarate by malate dehydrogenase [1-
40 3]. L-2-hydroxyglutarate dehydrogenase (L2HGDH) is the only enzyme known to oxidize
41 L-2-hydroxyglutarate back to α -ketoglutarate [2, 4]. In experiments, *L2HGDH* ablation
42 increases the accumulation of L-2-hydroxyglutarate in hypoxia [2, 5]. L-2-
43 hydroxyglutarate has been known to protect heart tissue from oxidative stress in
44 response to hypoxia [5]. Since coronary artery disease (CAD) leads to ischemic injury
45 and ischemia-reperfusion injury, L-2-hydroxyglutarate may play a protective role in CAD
46 and ischemic myocardial injury.

47
48 Metabolic remodeling plays a key role in the pathobiology of CAD and myocardial
49 infarction (MI) [5-7]. Recently, He and colleagues [5] discovered that genetic *L2HGDH*
50 deletion-induced L-2-hydroxyglutarate accumulation shows cardioprotective effects
51 under ischemic conditions in mice. They found that L-2-hydroxyglutarate accumulation
52 shifts glucose metabolisms from glycolysis to the pentose phosphate pathway in
53 response to low-flow ischemia or ischemia-reperfusion. This metabolic shift indicates
54 that *L2HGDH* deletion-induced L-2-hydroxyglutarate accumulation could reduce
55 ischemic myocardial damage by eliminating reactive oxygen species. The experiments
56 suggest that *L2HGDH* is a potential therapeutic target for oxidative stress-related
57 cardiovascular diseases, such as CAD and MI. However, there has been no prospective
58 clinical trial yet.

59
60 One genetic epidemiological approach for testing the causal effects of drug targets on
61 complex diseases is the Mendelian randomization (MR) method [8-12]. MR methods
62 can estimate the causal effects of putative risk factors based on germline genetic
63 variation in the population, without conducting a randomized controlled trial. Using the
64 drug-target MR framework, Ference and colleagues [8] determined the causal
65 associations of ATP citrate lyase (ACLY) and HMG-CoA reductase (HMGCR) inhibitions
66 with the risk of cardiovascular disease. Similarly, MR approaches could identify the
67 potentially causal associations of genetically proxied inhibition of cardiovascular drug
68 targets with cancers, neuropsychiatric diseases, and cognitive function [9-12].

69
70 Here, we conduct a two-sample MR study to assess putative causal effects of
71 genetically proxied inhibition of *L2HGDH* on CAD and MI (Figure 1). We construct
72 genetic instruments for *L2HGDH* that are associated with blood 2-hydroxyglutarate
73 levels. We then perform MR analysis to test whether this genetic instrument is causally
74 associated with CAD and MI using large-scale genome-wide association study (GWAS)
75 datasets.

76

77

78 **2. Methods**

79 **2.1. Mendelian randomization study design**

80 As illustrated in Figure 1, we designed a two-sample MR study to determine putative
81 causal effects of genetically proxied inhibition of *L2HGDH* on CAD and MI. We first

82 constructed the genetic instruments for *L2HGDH* to mimic pharmacological/genetic
83 perturbation of *L2HGDH* for increasing L-2-hydroxyglutarate levels. Due to the limited
84 availability of GWAS data for L-2-hydroxyglutarate levels, we constructed the genetic
85 instruments that are associated with 2-hydroxyglutarate level instead. We then
86 performed the Mendelian randomization analysis to determine potential causal
87 associations between the genetic instruments for *L2HGDH* and CAD using large-scale
88 GWAS summary statistics datasets.

89

90 **2.2. Genetic instruments for genetically proxied inhibition of *L2HGDH***

91 We obtained the GWAS summary statistics for human blood metabolome from Shin et
92 al [13]. Shin et al. [13] analyzed >400 blood metabolites from the KORA and TwinsUK
93 European population datasets using the Metabolon platform. Since the Metabolon
94 platform could not distinguish L-2-hydroxyglutarate from D-2-hydroxyglutarate, we
95 alternatively used the GWAS data for 2-hydroxyglutarate levels (accessed from
96 <https://gwas.mrcieu.ac.uk/>) to construct the genetic instruments for *L2HGDH*.

97

98 *L2HGDH* is the only enzyme known to catabolize L-2-hydroxyglutarate in human cells,
99 and *L2HGDH* inhibition increases L-2-hydroxyglutarate levels in experiments [1, 2].

100 Since 2-hydroxyglutarate includes both L-2-hydroxyglutarate and D-2-hydroxyglutarate,
101 we only considered *L2HGDH*-proxied genetic variants to mainly reflect L-2-
102 hydroxyglutarate levels. We constructed the genetic instruments for *L2HGDH* by
103 recruiting genetic variants within ± 500 kb from the *L2HGDH* gene that are associated
104 with blood 2-hydroxyglutarate level ($P < 0.05$) and that are also in low linkage

105 disequilibrium ($r^2 < 0.3$, with the default clumping window size of 10000 kb) [8]. The
106 characteristics of genetic variants proxied to *L2HGDH* are shown in Table S1. Since
107 there was no genome-wide significant variant near the *L2HGDH* gene (Table S2), we
108 adopted weak P-value and r^2 thresholds previously suggested by Ference and
109 colleagues [8]. The SNPs and *L2HGDH* gene were analyzed based on the GRCh37
110 (hg19) human genome reference (Figure S1). The PhenoScanner V2
111 (<http://www.phenoscaner.medschl.cam.ac.uk/>, accessed on Feb 6, 2023) was used to
112 identify pleiotropic variants (Table S3).

113

114 **2.3. Data sources for CAD and MI**

115 The GWAS summary statistics for CAD was obtained from the CARDIoGRAMplusC4D
116 (Coronary Artery Disease Genome-wide Replication and Meta-analysis plus Coronary
117 Artery Disease) 1000 Genomes-based GWAS meta-analysis study
118 (<http://www.cardiogramplusc4d.org>) [14]. The CARDIoGRAMplusC4D GWAS meta-
119 analysis dataset included genetic associations from 60,801 CAD cases and 123,504
120 controls mostly of European ancestry. The case status was defined by diagnosis of
121 CAD, including MI, acute coronary syndrome, chronic stable angina, and coronary
122 stenosis $>50\%$ [14]. In addition, the MI GWAS summary statistics was obtained from the
123 same CARDIoGRAMplusC4D meta-analysis study (34,541 MI cases and 261,984
124 controls). All the MI cases are a subpopulation of the CAD cases [14].

125

126 **2.4. Mendelian randomization and statistical analysis**

127 For MR analysis, the instrument strength was measured using the F-statistic. The F-
128 statistic less than 10 indicates weak instruments. We used the inverse-variance
129 weighted (IVW), weighted median, maximum likelihood, MR-PRESSO [15], Radial-MR
130 [16], and MR-RAPS [17] methods to evaluate the putative causal effects of genetically
131 proxied inhibition of *L2HGDH* on CAD and MI. The heterogeneity between SNPs was
132 evaluated by Cochran's Q test [18]. We also performed the MR Steiger directionality
133 test to determine the directionality of causality [19]. To assess potential directional and
134 horizontal pleiotropy, we used the MR-Egger intercept test and MR-PRESSO methods.
135 The leave-one-out sensitivity analysis and Radial-MR were used to detect potential
136 outlying genetic variants. $P < 0.05$ was considered statistically significant. All MR
137 analyses were performed in R (version 4.1.2, <https://www.r-project.org/>) with the
138 packages TwoSampleMR, MRPRESSO, and RadialMR.

139

140

141 **3. Results**

142 **3.1. Genetic instruments for *L2HGDH***

143 We first constructed the genetic instruments proxied to *L2HGDH* that are associated
144 with blood 2-hydroxyglutarate levels ($P < 0.05$) and that are also in low linkage
145 disequilibrium ($r^2 < 0.3$; Table S1). Since there was no genome-wide significant variant
146 associated with 2-hydroxyglutarate levels near the *L2HGDH* gene (Table S2), we
147 adopted a loose significance threshold of 0.05 to construct instruments for genetically
148 proxied inhibition of *L2HGDH* [8]. These genetic instruments mimic genetic or
149 pharmacological inhibition of *L2HGDH* for increasing blood 2-hydroxyglutarate levels

150 (Figure 1). The genetic instruments have the mean F-statistic of 7.661, indicating that
151 there might be a weak instrument bias in our MR analysis. The genetic instruments are
152 not associated with possible confounders or cardiovascular diseases/traits (Table S3).

153

154 **3.2. Association of genetically proxied inhibition of *L2HGDH* with CAD and MI**

155 We performed a two-sample MR analysis using the CARDIoGRAMplusC4D GWAS
156 meta-analysis dataset of CAD (60,801 CAD cases and 123,504 controls). As highlighted
157 in Table 1, the IVW method showed that genetically proxied inhibition of *L2HGDH*
158 associated with 2-hydroxyglutarate levels potentially decreased the risk of CAD (OR
159 0.486, 95% CI 0.242–0.977, $P=0.043$). There was no significant evidence of
160 heterogeneity (Cochran's Q-statistic=5.757, $P=0.674$). The radial IVW, weighted
161 median, and maximum likelihood methods also showed directionally similar estimates
162 (Table 1). The MR-RAPS method indicated that there might be a slightly weak
163 instrument bias (OR 0.460, 95% CI 0.202–1.046, $P=0.064$). The MR Steiger
164 directionality test confirmed the direction of the causality ($P<0.001$).

165

166 To assess potential directional horizontal pleiotropy, we used the MR-Egger and MR-
167 PRESSO methods. The MR-Egger intercept test determined that 9 genetic variants for
168 *L2HGDH* showed no evidence for significant pleiotropy (intercept=-0.014, $P=0.396$).
169 The MR-PRESSO global test also confirmed no significant horizontal pleiotropy with no
170 outlying genetic variants ($P=0.715$). In addition, the leave-one-out sensitivity analysis
171 showed that removing individual genetic variants did not substantially change the
172 estimated causal effect of genetically proxied inhibition of *L2HGDH* (Table S4). The

173 radial IVW method further confirmed no evidence of outlying genetic variants (Figure
174 S2). Taken together, the sensitivity analyses provide no significant evidence for
175 pleiotropic effects, which could bias the MR analysis.

176
177 As a subpopulation of the CAD cases, we also examined the putative causal
178 association between *L2HGDH* inhibition and MI using the CARDIoGRAMplusC4D meta-
179 analysis dataset of MI (34,541 MI cases and 261,984 controls). Using IVW, we found
180 that genetically proxied inhibition of *L2HGDH* was not significantly associated with the
181 risk of MI (OR 0.676, 95% CI 0.312–1.463, $P=0.320$). The MR-Egger intercept and MR-
182 PRESSO global tests indicated no significant pleiotropy (Table 1), and the radial plot
183 indicated no evidence of outlying variants (Figure S2).

184

185

186 **4. Discussion**

187 To our knowledge, this is the first MR study to demonstrate the potentially causal
188 association between genetically proxied inhibition of *L2HGDH* and CAD. Using two-
189 sample MR analyses, we revealed that genetically proxied inhibition of *L2HGDH* was
190 significantly associated with the decreased risk of CAD. The multiple MR sensitivity
191 analyses confirmed that this potential causal association was unlikely to be biased by
192 horizontal pleiotropy. Our findings suggests that genetic/pharmacological targeting of
193 *L2HGDH* may decrease the risk of CAD by increasing blood 2-hydroxyglutarate levels.
194 Since our genetic instruments are not directly associated with L-2-hydroxyglutarate

195 levels and there might be a weak instrument bias, further large-scale GWAS studies are
196 needed to obtain more robust and reliable MR results.

197

198 In the previous experimental study, *L2HGDH* deletion-induced L-2-hydroxyglutarate
199 accumulation protects the heart from redox stress, which plays a key role in myocardial
200 ischemic injury [5]. However, there has been no clinical trial to validate this potential
201 cardioprotective effect of *L2HGDH* inhibition. Using large-scale MR, we revealed that
202 genetically proxied inhibition of *L2HGDH* could potentially decrease the risk of CAD but
203 was not significantly associated with MI *per se* (Table 1). In our MR study, the CAD
204 cases include MI, acute coronary syndrome, coronary atherosclerosis, and chronic
205 ischemic heart diseases. Therefore, our findings suggest that *L2HGDH* inhibition may
206 play a cardioprotective role in not only being limited to myocardial ischemic damage, but
207 also in the primary prevention of CAD. The mechanisms underlying the potential
208 preventive effects of *L2HGDH* inhibition on CAD should be further investigated.

209

210 Due to the limited availability of GWAS data on blood metabolome, we constructed
211 genetic instruments based on blood 2-hydroxyglutarate levels, including its two
212 enantiomers L-2-hydroxyglutarate and D-2-hydroxyglutarate. D-2-hydroxyglutarate has
213 been known to be an oncometabolite in certain types of rare cancers [20, 21]. To
214 minimize the effects of D-2-hydroxyglutarate in our MR analysis, we constructed the
215 genetic instruments only proxied to the *L2HGDH* gene. In experiments, L-2-
216 hydroxyglutarate is the majority of 2-hydroxyglutarate, and *L2HGDH* but not *D2HGDH*
217 knockdown increases the concentration of 2-hydroxyglutarate [1, 2]. Additionally,

218 L2HGDH is the only reported enzyme that metabolizes L-2-hydroxyglutarate. Therefore,
219 our approach would mainly reflect *L2HGDH* inhibition-related L-2-hydroxyglutarate
220 levels; however, large-scale GWAS data of blood L-2-hydroxyglutarate levels is
221 essential to obtain more robust and reliable MR results. Since L-2-hydroxyglutarate is
222 also a putative oncometabolite in renal cell carcinoma [22, 23], further
223 epidemiological/clinical studies are warranted to determine the potential side effects of
224 *L2HGDH* inhibition.

225
226 A critical limitation of this study is that we adopted a loose P-value threshold of 0.05 to
227 build the genetic instruments [8]. When we used the genome-wide significance
228 threshold, there was no genetic variant associated with blood 2-hydroxyglutarate levels,
229 near the *L2HGDH* gene (Table S2). Since L2HGDH is the only enzyme known to
230 metabolize L-2-hydroxyglutarate, we only considered *L2HGDH*-proxied variants to
231 reflect the physiological effects of *L2HGDH* inhibition on L-2-hydroxyglutarate levels [1,
232 2]. In addition, we did not perform any replication analysis in non-European populations,
233 though the CARDIoGRAMplusC4D is the largest consortium study of CAD. Another
234 critical limitation is the underlying overlap between exposure and outcome datasets, as
235 the CARDIoGRAMplusC4D includes KORA (also known as GerMIFS III) and TwinsUK
236 (part of the PROCARDIS) datasets. This overlap could cause a bias towards
237 confounded associations in the two-sample MR [24]. In our MR analysis, the weighted
238 median methods did not show significant results; however, those methods are
239 statistically less powerful than IVW [25]. Large-scale multi-ancestry GWAS datasets for
240 L-2-hydroxyglutarate are essential to construct more robust genetic instruments.

241 Protein-protein interaction network analysis would be helpful to determine the functional
242 relationship between L2HGDH and the CAD disease module and to identify potential
243 drug targets [26, 27].

244

245

246 **5. Conclusion**

247 Our MR result suggests the potential association between genetically proxied inhibition
248 of *L2HGDH* and CAD, though there might be a weak instrument bias. Our findings may
249 have therapeutic implications for L2HGDH inhibitors in CAD. Further large-scale clinical
250 studies are needed to obtain more robust results.

251

252

253 **Authorship contribution**

254 Euijun Song designed, performed, analyzed data, and wrote the manuscript.

255

256

257 **Acknowledgements**

258 This research received no external funding. This study only used publicly available
259 GWAS summary statistics datasets. The author would like to thank Drs. Loscalzo and
260 Cheng for insightful discussions and comments.


261

262 References

- 263 1. Oldham, W.M., et al., *Hypoxia-Mediated Increases in L-2-hydroxyglutarate*
264 *Coordinate the Metabolic Response to Reductive Stress*. Cell Metab, 2015.
265 **22**(2): p. 291-303.
- 266 2. Intlekofer, A.M., et al., *Hypoxia Induces Production of L-2-Hydroxyglutarate*. Cell
267 Metab, 2015. **22**(2): p. 304-11.
- 268 3. Chakraborty, A.A., et al., *Histone demethylase KDM6A directly senses oxygen to*
269 *control chromatin and cell fate*. Science, 2019. **363**(6432): p. 1217-1222.
- 270 4. Rzem, R., et al., *A gene encoding a putative FAD-dependent L-2-*
271 *hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria*. Proc
272 Natl Acad Sci U S A, 2004. **101**(48): p. 16849-54.
- 273 5. He, H., et al., *L-2-Hydroxyglutarate Protects Against Cardiac Injury via Metabolic*
274 *Remodeling*. Circ Res, 2022. **131**(7): p. 562-579.
- 275 6. Xiao, W., et al., *Immunometabolic Endothelial Phenotypes: Integrating*
276 *Inflammation and Glucose Metabolism*. Circ Res, 2021. **129**(1): p. 9-29.
- 277 7. Lee, L.Y., et al., *Interferon-gamma Impairs Human Coronary Artery Endothelial*
278 *Glucose Metabolism by Tryptophan Catabolism and Activates Fatty Acid*
279 *Oxidation*. Circulation, 2021. **144**(20): p. 1612-1628.
- 280 8. Ference, B.A., et al., *Mendelian Randomization Study of ACLY and*
281 *Cardiovascular Disease*. N Engl J Med, 2019. **380**(11): p. 1033-1042.
- 282 9. Yarmolinsky, J., et al., *Genetically proxied therapeutic inhibition of*
283 *antihypertensive drug targets and risk of common cancers: A mendelian*
284 *randomization analysis*. PLoS Med, 2022. **19**(2): p. e1003897.
- 285 10. Sun, L., et al., *Associations of genetically proxied inhibition of HMG-CoA*
286 *reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer*. Breast
287 Cancer Res, 2022. **24**(1): p. 12.
- 288 11. Rosoff, D.B., et al., *Mendelian Randomization Study of PCSK9 and HMG-CoA*
289 *Reductase Inhibition and Cognitive Function*. J Am Coll Cardiol, 2022. **80**(7): p.
290 653-662.
- 291 12. Bell, A.S., et al., *Comparing the Relationships of Genetically Proxied PCSK9*
292 *Inhibition With Mood Disorders, Cognition, and Dementia Between Men and*

- 293 *Women: A Drug-Target Mendelian Randomization Study*. J Am Heart Assoc,
294 2022. **0**(0): p. e026122.
- 295 13. Shin, S.Y., et al., *An atlas of genetic influences on human blood metabolites*. Nat
296 Genet, 2014. **46**(6): p. 543-550.
- 297 14. Nikpay, M., et al., *A comprehensive 1,000 Genomes-based genome-wide
298 association meta-analysis of coronary artery disease*. Nat Genet, 2015. **47**(10):
299 p. 1121-1130.
- 300 15. Verbanck, M., et al., *Detection of widespread horizontal pleiotropy in causal
301 relationships inferred from Mendelian randomization between complex traits and
302 diseases*. Nat Genet, 2018. **50**(5): p. 693-698.
- 303 16. Bowden, J., et al., *Improving the visualization, interpretation and analysis of two-
304 sample summary data Mendelian randomization via the Radial plot and Radial
305 regression*. Int J Epidemiol, 2018. **47**(4): p. 1264-1278.
- 306 17. Zhao, Q., et al., *Statistical inference in two-sample summary-data Mendelian
307 randomization using robust adjusted profile score*. The Annals of Statistics, 2020.
308 **48**(3): p. 1742-1769.
- 309 18. Burgess, S., et al., *Sensitivity Analyses for Robust Causal Inference from
310 Mendelian Randomization Analyses with Multiple Genetic Variants*.
311 Epidemiology, 2017. **28**(1): p. 30-42.
- 312 19. Hemani, G., K. Tilling, and G. Davey Smith, *Orienting the causal relationship
313 between imprecisely measured traits using GWAS summary data*. PLoS Genet,
314 2017. **13**(11): p. e1007081.
- 315 20. Rakheja, D., et al., *The emerging role of d-2-hydroxyglutarate as an
316 oncometabolite in hematolymphoid and central nervous system neoplasms*. Front
317 Oncol, 2013. **3**: p. 169.
- 318 21. Jezek, P., *2-Hydroxyglutarate in Cancer Cells*. Antioxid Redox Signal, 2020.
319 **33**(13): p. 903-926.
- 320 22. Shelar, S., et al., *Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate,
321 a Potential Therapeutic Target in Renal Cancer*. Clin Cancer Res, 2018. **24**(24):
322 p. 6433-6446.

- 323 23. Shim, E.H., et al., *L-2-Hydroxyglutarate: an epigenetic modifier and putative*
324 *oncometabolite in renal cancer*. *Cancer Discov*, 2014. **4**(11): p. 1290-8.
- 325 24. Burgess, S., N.M. Davies, and S.G. Thompson, *Bias due to participant overlap in*
326 *two-sample Mendelian randomization*. *Genet Epidemiol*, 2016. **40**(7): p. 597-608.
- 327 25. Bowden, J., *Misconceptions on the use of MR-Egger regression and the*
328 *evaluation of the InSIDE assumption*. *Int J Epidemiol*, 2017. **46**(6): p. 2097-2099.
- 329 26. Cheng, F., et al., *Network-based approach to prediction and population-based*
330 *validation of in silico drug repurposing*. *Nat Commun*, 2018. **9**(1): p. 2691.
- 331 27. Lee, L.Y., et al., *Network medicine in Cardiovascular Research*. *Cardiovasc Res*,
332 2021. **117**(10): p. 2186-2202.
- 333



334

335 **Figure 1.** Overall analysis scheme. (A) Function of L-2-hydroxyglutarate

336 dehydrogenase (L2HGDH) in energy metabolisms. Inhibition of L2HGDH increases

337 blood L-2-hydroxyglutarate levels. (B) We constructed genetic instruments proxied to

338 the *L2HGDH* gene that are associated with blood 2-hydroxyglutarate levels. We then

339 performed two-sample Mendelian randomization analysis to assess the causal effects of

340 genetically proxied inhibition of *L2HGDH* on coronary artery disease and myocardial

341 infarction.

342

343 **Table 1.** Mendelian randomization (MR) analyses for causal associations of genetically proxied inhibition of *L2HGDH* with
 344 coronary artery disease and myocardial infarction.

	Coronary artery disease (60,801 cases, 123,504 controls)			Myocardial infarction (34,541 cases, 261,984 controls)		
	OR (95% CI)	P-value	SNPs	OR (95% CI)	P-value	SNPs
IVW	0.486 (0.242–0.977)	0.043	9	0.676 (0.312–1.463)	0.320	9
IVW (Radial)	0.487 (0.269–0.880)	0.017	9	0.676 (0.361–1.268)	0.222	9
Weighted median	0.762 (0.300–1.937)	0.568	9	0.888 (0.325–2.428)	0.817	9
Maximum likelihood	0.457 (0.216–0.967)	0.041	9	0.655 (0.291–1.476)	0.308	9
MR-RAPS	0.460 (0.202–1.046)	0.064	9	0.681 (0.284–1.630)	0.388	9
MR-Egger intercept*	-0.014 (0.016)	0.396	9	-0.004 (0.017)	0.836	9
MR-PRESSO global [#]	-	0.715	9	-	0.752	9
MR Steiger directionality	-	<0.001	9	-	<0.001	9


345 SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted method.

346 *Intercept values are presented with SE.

347 [#]No outlying genetic variants were detected.


348

349 **Supplementary materials**



350
351 **Figure S1.** Genomic positions of nine genetic instruments for genetically proxied
352 inhibition of *L2HGDH*. The genomic positions were visualized using the NCBI Graphical
353 Sequence Viewer (GRCh37, accessed on Oct 29, 2022).

354



355

356 **Figure S2.** Radial inverse-variance weighted (IVW) Mendelian randomization plots for
357 coronary artery disease (A) and myocardial infarction (B). Black dots indicate valid
358 genetic variants. The estimated effect sizes are presented. There is no outlier variant in
359 the present radial plots.

360

361 **Table S1.** Nine *L2HGDH*-proxied (\pm 500 kb) genetic variants that are associated with
362 blood 2-hydroxyglutarate levels ($P < 0.05$, $r^2 < 0.3$).

SNP	Position (GRCh37)	EA/OA	EAF	β (SE)*	P-value	F- statistic
rs11628742	chr14:50515075	C/T	0.438	-0.0112 (0.0043)	9.02×10^{-3}	6.784
rs11625406	chr14:50516192	A/C	0.619	0.0070 (0.0033)	3.56×10^{-2}	4.500
rs8017367	chr14:50675487	T/C	0.261	-0.0121 (0.0034)	4.00×10^{-4}	12.665
rs12894758	chr14:50760030	T/C	0.291	0.0135 (0.0034)	6.80×10^{-5}	15.766
rs9323183	chr14:50796881	C/G	0.054	-0.0150 (0.0071)	3.37×10^{-2}	4.463
rs11570815	chr14:50825258	T/A	0.662	0.0094 (0.0033)	4.88×10^{-3}	8.114
rs17791680	chr14:50965445	A/G	0.372	-0.0081 (0.0034)	1.64×10^{-2}	5.676
rs2144975	chr14:50969448	C/T	0.955	0.0170 (0.0075)	2.44×10^{-2}	5.138
rs2012893	chr14:51073443	G/A	0.088	-0.0145 (0.0060)	1.53×10^{-2}	5.840

363 SNP, single nucleotide polymorphism; EA, effect allele; OA, other allele; EAF, effective
364 allele frequency.

365 *Log(odds ratio) per 1-SD increase in blood 2-hydroxyglutarate levels.

366

367 **Table S2.** Genetic variants associated with blood 2-hydroxyglutarate levels ($P < 1 \times 10^{-5}$,
368 $r^2 < 0.3$).

SNP	Position (GRCh37)	EA/OA	EAF	β (SE)*	P-value
rs10196007	chr2:145329033	C/T	0.184	0.0320 (0.0065)	7.63×10^{-7}
rs1568101	chr3:148590090	T/C	0.912	-0.0255 (0.0057)	8.62×10^{-6}
rs7725624	chr5:63010725	A/C	0.087	-0.0440 (0.0094)	3.02×10^{-6}
rs7702827	chr5:158879869	G/C	0.700	0.0152 (0.0034)	6.29×10^{-6}
rs933341	chr7:83743619	G/A	0.760	-0.0166 (0.0035)	1.56×10^{-6}
rs8176023	chr7:142642596	G/A	0.072	0.0411 (0.0087)	2.46×10^{-6}
rs890519	chr8:18905049	A/C	0.416	0.0147 (0.0033)	9.06×10^{-6}
rs10966201	chr9:24079188	C/T	0.345	-0.0151 (0.0034)	7.11×10^{-6}
rs11793331	chr9:133298199	T/C	0.024	0.0619 (0.0136)	5.09×10^{-6}
rs6484669	chr11:11120287	C/T	0.259	0.0196 (0.0044)	7.75×10^{-6}
rs9544785	chr13:78971070	A/C	0.361	-0.0150 (0.0033)	6.63×10^{-6}
rs16977497	chr17:71021645	A/G	0.045	0.0538 (0.0122)	9.91×10^{-6}
rs6064820	chr20:58206004	T/C	0.723	0.0155 (0.0034)	4.01×10^{-6}

369 SNP, single nucleotide polymorphism; EA, effect allele; OA, other allele; EAF, effective
370 allele frequency.

371 *Log(odds ratio) per 1-SD increase in blood 2-hydroxyglutarate levels.

372

373 **Table S3.** Phenotypes associated with the *L2HGDH*-proxied genetic instruments based
374 on PhenoScanner V2 (accessed on Feb 6, 2023).

SNP	Associated phenotypes ($P < 1 \times 10^{-5}$)
rs11628742	-
rs11625406	-
rs8017367	-
rs12894758	Impedance of arm right; Impedance of arm left
rs9323183	-
rs11570815	-
rs17791680	Impedance of arm right; Impedance of arm left; Sitting height; Arm fat-free mass right
rs2144975	Treatment with inderal 10mg tablet
rs2012893	-

375

376 **Table S4.** Leave-one-out sensitivity analyses for the causal associations of genetically
 377 proxied *L2HGDH* inhibition with coronary artery disease and myocardial infarction using
 378 the inverse-variance weighted method.

Removed SNP	Coronary artery disease		Myocardial infarction	
	OR (95% CI)	P-value	OR (95% CI)	P-value
rs2144975	0.576 (0.277–1.194)	0.138	0.826 (0.369–1.847)	0.641
rs11570815	0.545 (0.259–1.150)	0.111	0.770 (0.337–1.758)	0.535
rs11625406	0.535 (0.260–1.103)	0.090	0.715 (0.321–1.590)	0.410
rs17791680	0.499 (0.240–1.036)	0.062	0.668 (0.297–1.499)	0.328
rs9323183	0.461 (0.225–0.945)	0.035	0.644 (0.291–1.425)	0.278
rs2012893	0.457 (0.222–0.941)	0.034	0.657 (0.296–1.461)	0.304
rs8017367	0.455 (0.212–0.979)	0.044	0.553 (0.237–1.289)	0.170
rs11628742	0.445 (0.209–0.947)	0.036	0.625 (0.271–1.442)	0.270
rs12894758	0.411 (0.188–0.899)	0.026	0.648 (0.272–1.542)	0.326
None (original)	0.486 (0.242–0.977)	0.043	0.676 (0.312–1.463)	0.320

379 SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

380